Heron Therapeutics (HRTX) Gross Profit (2017 - 2026)

Heron Therapeutics has reported Gross Profit for 10 years, with the latest figure at $24.1 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit fell 20.93% year-over-year to $24.1 million; the trailing twelve-month figure through Mar 2026 stood at $107.2 million (down 2.43% YoY), and the FY2025 full-year result was $113.6 million, up 7.5% from the prior year.
• Gross Profit for Q1 2026 stood at $24.1 million, down from $29.5 million in the prior quarter.
• The five-year high for Gross Profit was $30.6 million in Q4 2024, with the low at $11.5 million in Q2 2022.
• Historically, Gross Profit has averaged $21.1 million across 5 years, with a median of $24.1 million in 2026.
• Annual changes were most pronounced in 2022 — Gross Profit surged 155.34% — and 2026, when it fell 20.93%.
• Heron Therapeutics' Gross Profit stood at $17.4 million in 2022, then surged by 39.92% to $24.3 million in 2023, then rose by 25.48% to $30.6 million in 2024, then declined by 3.55% to $29.5 million in 2025, then retreated by 18.31% to $24.1 million in 2026.
• The last three Gross Profit figures came in at $24.1 million (Q1 2026), $29.5 million (Q4 2025), and $26.3 million (Q3 2025), per Business Quant data.